Dataset Information

The CanPain SCI clinical practice guidelines for rehabilitation management of neuropathic pain after spinal cord injury: 2021 update.

ABSTRACT:

Study design

Clinical practice guidelines.

Objectives

The objective was to update the 2016 version of the Canadian clinical practice guidelines for the management of neuropathic pain in people with spinal cord injury (SCI).

Setting

The guidelines are relevant for inpatient, outpatient and community SCI rehabilitation settings in Canada.

Methods

The guidelines were updated in accordance with the Appraisal of Guidelines for Research and Evaluation II tool. A Steering Committee and Working Group reviewed the relevant evidence on neuropathic pain management (encompassing screening and diagnosis, treatment and models of care) after SCI. The quality of evidence was scored using Grading of Recommendations Assessment, Development and Evaluation (GRADE). A consensus process was followed to achieve agreement on recommendations and clinical considerations.

Results

The working group identified and reviewed 46 additional relevant articles published since the last version of the guidelines. The panel agreed on 3 new screening and diagnosis recommendations and 8 new treatment recommendations. Two key changes to these treatment recommendations included the introduction of general treatment principles and a new treatment recommendation classification system. No new recommendations to model of care were made.

Conclusions

The CanPainSCI recommendations for the management of neuropathic pain after SCI should be used to inform practice.

SUBMITTER: Loh E

PROVIDER: S-EPMC9209331 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The CanPain SCI clinical practice guidelines for rehabilitation management of neuropathic pain after spinal cord injury: 2021 update.

Loh Eldon E Mirkowski Magdalena M Agudelo Alexandria Roa AR Allison David J DJ Benton Brooke B Bryce Thomas N TN Guilcher Sara S Jeji Tara T Kras-Dupuis Anna A Kreutzwiser Denise D Lanizi Oda O Lee-Tai-Fuy Gary G Middleton James W JW Moulin Dwight E DE O'Connell Colleen C Orenczuk Steve S Potter Patrick P Short Christine C Teasell Robert R Townson Andrea A Widerström-Noga Eva E Wolfe Dalton L DL Xia Nancy N Mehta Swati S

Spinal cord 20220205 6

<h4>Study design</h4>Clinical practice guidelines.<h4>Objectives</h4>The objective was to update the 2016 version of the Canadian clinical practice guidelines for the management of neuropathic pain in people with spinal cord injury (SCI).<h4>Setting</h4>The guidelines are relevant for inpatient, outpatient and community SCI rehabilitation settings in Canada.<h4>Methods</h4>The guidelines were updated in accordance with the Appraisal of Guidelines for Research and Evaluation II tool. A Steering C ...[more]

PMID: 35124700

Similar Datasets

Project description:Objective: Chronic pain is a major problem in patients with spinal cord injury (SCI). According to different studies, approximately 70% of patients with SCI experience persistent pain. Although previous gene expression profiling studies have been conducted in animal models, gene expression profiling study in human whole blood has not been reported yet. The objective of this study was to define the gene expression profile of neuropathic pain in spinal cord injured patients. Materials and Methods: We performed gene expression analysis including 20.000 genes using Affymetrix GeneChip® Primeview™ Human Gene Expression Arrays. For confirmation of expression levels of selected genes, we performed real time polymerase chain reaction. We gathered samples from periferic blood mononuclear cells. Data of twelve patients with intractable neuropathic pain was compared with thirteen patients who don’t have pain. All patients have complete injuries with a level of injury above T5. Results: A total of 16 differentially expressed genes including 9 up-regulated and 7 down-regulated were obtained with a cut-off degree at 4 fold change. EIF1AY, RPS4Y1, DDX3Y, RPL31, ETS1, KLF3, JUN, CYorf15B, and ERAP2 were in up-regulated and HLA-C, XIST, C4BPA, FAM118A, ZNF506, OVOS2, and C1D were in down-regulated group. KEGG pathway database showed that 14.6% of genes were enriched in the nodes of immune system. Real time polymerase chain reaction analyses did not increase to statistically significant levels for confirmation of gene expression analyze results. Conclusions: Considering these data, findings of this first gene expression study in humans with SCI might provide valuable information for future targets for understanding neuropathic pain pathogenesis. The results of gene expression analyses were not confirmed by real time polymerase chain reaction. Studies with larger sample size are needed for confirmation. This is a cross-sectional study with a control group. Patients were divided into two groups according to intractable neuropathic pain existence.There were 12 patients in group A (Patients with pain) and 13 patients in control group.

Dataset Information

The CanPain SCI clinical practice guidelines for rehabilitation management of neuropathic pain after spinal cord injury: 2021 update.

Study design

Objectives

Setting

Methods

Results

Conclusions

Publications

The CanPain SCI clinical practice guidelines for rehabilitation management of neuropathic pain after spinal cord injury: 2021 update.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets